# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Vernon Bernardino maintains Cassava Sciences (NASDAQ:SAVA) with a Buy and raises the price t...
Current Updates on Phase 3 Clinical ProgramBackground - Our Phase 3 program consists of two global, double-blind, randomized, p...
Cassava Sciences (NASDAQ:SAVA) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0....
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.